期刊文献+

Anti-hyperuricemic and anti-inflammatory actions of vaticaffinol isolated from Dipterocarpus alatus in hyperuricemic mice 被引量:6

Anti-hyperuricemic and anti-inflammatory actions of vaticaffinol isolated from Dipterocarpus alatus in hyperuricemic mice
原文传递
导出
摘要 The present study was designed to examine the anti-hyperuricemic and anti-inflammatory effects and possible mechanisms of vaticaffinol, a resveratrol tetramer isolated from ethanol extracts of Dipterocarpus alatus, in oxonate-induced hyperuricemic mice. At 1 h after 250 mg·kg^(-1) potassium oxonate was given, vaticaffinol at 20, 40, and 60 mg·kg^(-1) was intragastrically administered to hyperuricemic mice once daily for seven consecutive days. Vaticaffinol significantly decreased serum uric acid levels and improved kidney function in hyperuricemic mice. It inhibited hepatic activity of xanthine dehydrogenase(XDH) and xanthine oxidase(XOD), regulated renal m RNA and protein levels of urate transporter 1(URAT1), glucose transporter 9(GLUT9), organic anion transporter 1(OAT1), organic cation transporter 1(OCT1), OCT2, organic cation/carnitine transporter 1(OCTN1), and OCTN2 in hyperuricemic mice. Moreover, vaticaffinol markedly down-regulated renal protein levels of NOD-like receptor 3(NLRP3), apoptosis-associated speck-like(ASC), and Caspase-1, resulting in the reduction of interleukin(IL)-1β, IL-18, IL-6 and tumor necrosis factor-α(TNF-α) levels in this animal model. Additionally, HPLC and LC-MS analyses clearly testified the presence of vaticaffinol in the crude extract. These results suggest that vaticaffinol may be useful for the prevention and treatment of hyperuricemia with kidney inflammation. The present study was designed to examine the anti-hyperuricemic and anti-inflammatory effects and possible mechanisms of vaticaffinol, a resveratrol tetramer isolated from ethanol extracts of Dipterocarpus alatus, in oxonate-induced hyperuricemic mice. At 1 h after 250 mg·kg^(-1) potassium oxonate was given, vaticaffinol at 20, 40, and 60 mg·kg^(-1) was intragastrically administered to hyperuricemic mice once daily for seven consecutive days. Vaticaffinol significantly decreased serum uric acid levels and improved kidney function in hyperuricemic mice. It inhibited hepatic activity of xanthine dehydrogenase(XDH) and xanthine oxidase(XOD), regulated renal m RNA and protein levels of urate transporter 1(URAT1), glucose transporter 9(GLUT9), organic anion transporter 1(OAT1), organic cation transporter 1(OCT1), OCT2, organic cation/carnitine transporter 1(OCTN1), and OCTN2 in hyperuricemic mice. Moreover, vaticaffinol markedly down-regulated renal protein levels of NOD-like receptor 3(NLRP3), apoptosis-associated speck-like(ASC), and Caspase-1, resulting in the reduction of interleukin(IL)-1β, IL-18, IL-6 and tumor necrosis factor-α(TNF-α) levels in this animal model. Additionally, HPLC and LC-MS analyses clearly testified the presence of vaticaffinol in the crude extract. These results suggest that vaticaffinol may be useful for the prevention and treatment of hyperuricemia with kidney inflammation.
出处 《Chinese Journal of Natural Medicines》 SCIE CAS CSCD 2017年第5期330-340,共11页 中国天然药物(英文版)
基金 supported by grants from Program for Changjiang Scholars and Innovative Research Team in University(IRT_14R271020)
关键词 Dipterocarpus alatus Vaticaffinol Anti-hyperuricemic effect Kidney organic ion transporters Kidney inflammation Dipterocarpus alatus Vaticaffinol Anti-hyperuricemic effect Kidney organic ion transporters Kidney inflammation
  • 相关文献

参考文献1

二级参考文献34

  • 1Singh JA, Reddy SG, Kundukulam J. Risk factors for gout and prevention: a systematic review of the literature [J]. Curr Opin Rheumatol, 2011, 23(2): 192-202.
  • 2Mellen PB, Bleyer AJ, Erlinger TP, et al. Serum uric acid predicts incident hypertension in a biethnic cohort the atherosclerosis risk in communities study [J]. Hypertension, 2006, 48(6): 1037-1042.
  • 3Zhu Y, Pandya BJ, Choi HK. Comorbidities of gout and hyperuricemia in the US general population: NHANES 2007-2008 [J]. Am JMed, 2012, 125(7): 679-687.
  • 4Kong LD, Yang C, Ge F, et al. A Chinese herbal medicine Ermiao wan reduces serum uric acid level and inhibits liver xanthine dehydrogenase and xanthine oxidase in mice [J]. J Ethnopharmacol, 2004.93(2-3): 325-330.
  • 5Ichida K, Hosoyamada M, Hisatome 1, et al. Clinical and molecular analysis of patients with renal hypouricemia in Japan-influence ofURAT1 gene on urinary urate excretion [J]. JAm Soc Nephrol, 2004, 15(1): 164-173.
  • 6Hirotaka M, Toshinori C, Shushi N. Mutations in glucose transporter 9 gene SLC2A9 cause renal hyperuricemia [J]. Am Soc Human Genet, 2008, 83(6): 744-751.
  • 7Koepsell H, Endou H. The SLC22 drug transporter family [J]. Pflugers Archiv-Eur J Physiol, 2004, 447(5): 666-676.
  • 8Eraly SA, Vallon V, Rieg T, et al. Multiple organic anion transporters contribute to net renal excretion of uric acid [J]. Physiol Genomics, 2008, 33(2): 180-192.
  • 9Woodward OM, Kottgen A, Coresh J, et al. Identification of a urate transporter, ABCG2, with a common functional polymorphism causing gout [J]. Proc Natl Acad Sci, 2009, 106(25): 10338-10342.
  • 10Sakurai HI. Urate transporters in the genomic era [J]. Curr Opin Nephrol Hypertens, 2013, 22(5): 545-550.

共引文献11

同被引文献131

引证文献6

二级引证文献49

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部